Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?

B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes

(2011) Christina Tekle et al.   INTERNATIONAL JOURNAL OF CANCER

Does a tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer?

(2010) Einar Servoll et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

Enhancing the efficacy of cancer vaccines in urologic oncology: new directions

(2009) Sergei Kusmartsev et al.   Nature Reviews Urology

Immune infiltration in human tumors: a prognostic factor that should not be ignored

(2009) F Pagès et al.   ONCOGENE

Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma

(2008) P. L. Crispen et al.   CLINICAL CANCER RESEARCH

Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses

(2008) M. Hashiguchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The complex role of B7 molecules in tumor immunology

(2008) Barbara Seliger et al.   TRENDS IN MOLECULAR MEDICINE